Aberrant cell surface glycosylation is prevalent in tumor cells, and there is ample evidence that glycans have functional roles in carcinogenesis. Nonetheless, many molecular details remain unclear. Tumor cells frequently exhibit increased ␣2-6 sialylation on N-glycans, a modification that is added by the ST6Gal-I sialyltransferase, and emerging evidence suggests that ST6Gal-I-mediated sialylation promotes the survival of tumor cells exposed to various cell stressors. Here we report that ST6Gal-I protects cancer cells from hypoxic stress. It is well known that hypoxia-inducible factor 1␣ (HIF-1␣) is stabilized in hypoxic cells, and, in turn, HIF-1␣ directs the transcription of genes important for cell survival. To investigate a putative role for ST6Gal-I in the hypoxic response, we examined HIF-1␣ accumulation in ovarian and pancreatic cancer cells in ST6Gal-I overexpression or knockdown experiments. We found that ST6Gal-I activity augmented HIF-1␣ accumulation in cells grown in a hypoxic environment or treated with two chemical hypoxia mimetics, deferoxamine and dimethyloxalylglycine. Correspondingly, hypoxic cells with high ST6Gal-I expression had increased mRNA levels of HIF-1␣ transcriptional targets, including the glucose transporter genes GLUT1 and GLUT3 and the glycolytic enzyme gene PDHK1. Interestingly, high ST6Gal-I-expressing cells also had an increased pool of HIF-1␣ mRNA, suggesting that ST6Gal-I may influence HIF-1␣ expression. Finally, cells grown in hypoxia for several weeks displayed enriched ST6Gal-I expression, consistent with a pro-survival function. Taken together, these findings unravel a glycosylation-dependent mechanism that facilitates tumor cell adaptation to a hypoxic milieu.
Aberrant cell surface glycosylation is prevalent in tumor cells, and there is ample evidence that glycans have functional roles in carcinogenesis. Nonetheless, many molecular details remain unclear. Tumor cells frequently exhibit increased ␣2-6 sialylation on N-glycans, a modification that is added by the ST6Gal-I sialyltransferase, and emerging evidence suggests that ST6Gal-I-mediated sialylation promotes the survival of tumor cells exposed to various cell stressors. Here we report that ST6Gal-I protects cancer cells from hypoxic stress. It is well known that hypoxia-inducible factor 1␣ (HIF-1␣) is stabilized in hypoxic cells, and, in turn, HIF-1␣ directs the transcription of genes important for cell survival. To investigate a putative role for ST6Gal-I in the hypoxic response, we examined HIF-1␣ accumulation in ovarian and pancreatic cancer cells in ST6Gal-I overexpression or knockdown experiments. We found that ST6Gal-I activity augmented HIF-1␣ accumulation in cells grown in a hypoxic environment or treated with two chemical hypoxia mimetics, deferoxamine and dimethyloxalylglycine. Correspondingly, hypoxic cells with high ST6Gal-I expression had increased mRNA levels of HIF-1␣ transcriptional targets, including the glucose transporter genes GLUT1 and GLUT3 and the glycolytic enzyme gene PDHK1. Interestingly, high ST6Gal-I-expressing cells also had an increased pool of HIF-1␣ mRNA, suggesting that ST6Gal-I may influence HIF-1␣ expression. Finally, cells grown in hypoxia for several weeks displayed enriched ST6Gal-I expression, consistent with a pro-survival function. Taken together, these findings unravel a glycosylation-dependent mechanism that facilitates tumor cell adaptation to a hypoxic milieu.
The tumor microenvironment plays a prominent role in regulating cancer cell behavior. One major microenvironmental factor that influences tumor cell phenotype is oxygen availability. Hypoxic areas within tumors are well-established niches for stem-like cancer cells, referred to as cancer stem cells (CSCs). 2 Furthermore, exposing tumor cells to low oxygen tension promotes CSC characteristics, suggesting that hypoxia actively reprograms cells to acquire stem-like properties. Under conditions of oxygen deprivation, a variety of cell signaling pathways become activated. Among these, the hypoxia-inducible factor (HIF) family of transcription factors serves as a principal mediator of the cell response to hypoxia. HIF proteins, such as HIF-1␣, are constitutively synthesized but rapidly degraded under normoxic conditions. When oxygen is replete, HIF-1␣ is hydroxylated by prolyl hydroxylase enzymes, an event that targets HIF-1␣ for ubiquitination and proteolytic degradation. In low oxygen tension, the lack of HIF-1␣ hydroxylation stabilizes the protein, allowing HIF-1␣ to bind HIF-1␤, and translocate into the nucleus to direct the transcription of genes that enable tumor cell survival within the hypoxic milieu. In particular, HIF-1␣ up-regulates angiogenic genes that stimulate tumor vascularization as well as metabolic genes that facilitate anaerobic glycolysis (1, 2) . In addition, HIF-dependent transcriptional activity is a key contributor to the CSC phenotype (3) (4) (5) (6) (7) .
Deciphering the molecular mechanisms that foster tumor cell adaptation to hypoxia represents an exceptionally active area of investigation; however, the role of the tumor glycome in this process has received limited attention. Glycans lie at the interface between the extracellular environment and intracellular signaling events that dictate cell response to the external milieu. Cell surface receptors are extensively decorated with glycoconjugates, and these function to modify the activity of the cognate proteins that carry these structures. For example, sialic acid, a negatively charged sugar, can markedly alter receptor conformation, oligomerization, and/or surface retention, depending on the specific protein carrier. As a consequence, receptor glycosylation tunes receptor-driven signaling cascades that control tumor cell behavior.
Changes in the composition of receptor glycans on malignant cells are well-documented. There is a distinct subset of glycan structures commonly up-regulated in cancer, including sialyl Lewis antigens, complex ␤1,6-branched N-glycans, and truncated O-glycans (e.g. Tn and sialyl Tn) (8 -12) . Another prevalent tumor-associated alteration is an increase in the amount of ␣2-6 -linked sialic acid added to N-glycans, a modification elaborated by the ST6Gal-I sialyltransferase (13) (14) (15) (16) (17) . ST6Gal-I is up-regulated in numerous types of epithelial cancers, and high ST6Gal-I expression is associated with a poor patient prognosis in breast, ovarian, colon, and pancreatic adenocarcinoma (18 -22) . Recent studies suggest that a central cornerstone of ST6Gal-I's pro-tumorigenic function is its role in conferring a CSC phenotype (18) . ST6Gal-I expression correlates with established CSC markers such ALDH1 and CD133 (19) , and ST6Gal-I activity imparts hallmark CSC characteristics, including tumor spheroid growth, cell invasiveness, tumor-initiating potential, and resistance to cytotoxic stimuli, including chemotherapeutic drugs (18, (23) (24) (25) (26) (27) (28) (29) (30) (31) . ST6Gal-I also promotes epithelial-to-mesenchymal transition (32) .
In view of evidence suggesting that ST6Gal-I endows tumor cells with CSC-like properties, we investigated whether ST6Gal-I is involved in the cellular response to hypoxia. ST6Gal-I was overexpressed or knocked down in various pancreatic and ovarian cancer cell lines, and the hypoxia-induced activation of HIF-1␣ signaling was examined. We report that cells with high ST6Gal-I expression have elevated levels of HIF-1␣ protein upon exposure to either chemical hypoxia mimetics or incubation in a hypoxia chamber. Moreover, longterm cell growth in hypoxia selects for a population with enhanced ST6Gal-I expression. Consistent with HIF-1␣ enrichment, high ST6Gal-I expressers exhibit increased transcription of HIF-1␣ target genes, including the glucose transporters GLUT1 and GLUT3 and the glycolytic enzyme pyruvate dehydrogenase kinase 1 (PDHK1). Finally, hypoxic cells with high ST6Gal-I expression have increased levels of HIF-1␣ mRNA, thus poising the cell for greater HIF-1␣ accumulation upon protein stabilization. These collective results point to a novel role for tumor cell glycans in aiding tumor cell survival within hypoxic microenvironments.
Results

ST6Gal-I regulates HIF-1␣ accumulation after hypoxia chemical mimetic treatment
To investigate the role of ST6Gal-I in hypoxia signaling, we modulated ST6Gal-I expression in two ovarian cancer lines, OV4 and PA-1, and one pancreatic cancer line, MiaPaCa-2. ST6Gal-I was stably overexpressed in the OV4 line ( Fig. 1A) , which is one of the few cancer lines that lacks detectable ST6Gal-I protein. As a control, OV4 cells were stably transduced with an empty lentiviral vector (EV). Contrarily, ST6Gal-I was stably knocked down in the MiaPaCa-2 and PA-1 cell lines, both of which have high endogenous ST6Gal-I expression ( Fig. 1, B and C). To confirm that manipulation of ST6Gal-I expression correlated with changes in surface sialylation, cells were stained with the SNA lectin, which specifically recognizes ␣2-6 -linked sialic acids, and evaluated by flow cytometry. ST6Gal-I OE in OV4 cells led to an increase in SNA reactivity ( Fig. 1D ), whereas SNA staining was diminished by ST6Gal-I KD in MiaPaCa-2 and PA-1 cells (Fig. 1 , E and F).
Cells with variant ST6Gal-I expression were cultured in the presence or absence of the chemical hypoxia mimetic desferoxamine (DFO), an iron chelator that prevents cells from binding oxygen. In the OV4 line, greater accumulation of HIF-1␣ was observed in DFO-treated OE cells compared with EV cells (Fig.  1G ). No detectable HIF-1␣ protein expression was apparent in the absence of DFO treatment, consistent with the extensive literature indicating that HIF-1␣ is constitutively degraded under normoxic conditions (1, (33) (34) (35) . In MiaPaCa-2 and PA-1 cells, KD of ST6Gal-I caused a reduction in DFO-dependent HIF-1␣ expression ( Fig. 1, H and I) .
The role of ST6Gal-I in HIF-1␣ accumulation was also examined using a second chemical hypoxia mimetic, dimethyloxalylglycine (DMOG). DMOG is a specific inhibitor of prolyl hydroxylase, an enzyme that hydroxylates HIF-1␣ to target it for proteasomal degradation. Cells were treated with DMOG for 24 h and then immunoblotted for HIF-1␣. As shown in Fig.  2A , HIF-1␣ was more abundant in DMOG-treated OV4 OE cells versus EV cells, whereas ST6Gal-I KD in MiaPaCa-2 cells diminished DMOG-induced HIF-1␣ levels (Fig. 2B ). Interestingly, striking differences in cell morphology were apparent in DMOG-treated cells (Fig. 2C ). DMOG treatment of OV4 EV cells (which lack ST6Gal-I) caused cell rounding and detachment from the plate, indicative of cell death. Notably, ST6Gal-I OE in OV4 cells had a strong protective effect against DMOG toxicity. Consistent with these results, DMOG did not alter the morphology of MiaPaCa-2 EV cells (with high endogenous ST6Gal-I), whereas substantial DMOG-induced cell detachment was apparent in ST6Gal-I KD cells. These results are in line with emerging literature highlighting ST6Gal-I as a potent tumor cell survival factor (18, 36 -38). 
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ST6Gal-I activity enhances HIF-1␣ accumulation in physiological hypoxia
We next examined the contribution of ST6Gal-I to HIF-1␣ accumulation in cells exposed to physiological hypoxia. OV4 cells were grown for 24 h under either standard culture conditions (normoxia) or in a 2% oxygen chamber (hypoxia). After culture in hypoxia, OV4 OE cells exhibited increased levels of HIF-1␣ compared with EV cells (Fig. 3A) . No detectable HIF-1␣ protein was observed in cells grown in normoxia, as expected. For the PA-1 line, cells were cultured in 0.5% O 2 , as these cells appeared to be less sensitive to hypoxia than OV4 cells. Compared with PA-1 EV cells, ST6Gal-I KD cells had reduced levels of HIF-1␣ protein at both 12 and 24 h after hypoxic growth ( Fig. 3B ). We also overexpressed ST6Gal-I in the PA-1 line and found that ST6Gal-I OE cells cultured in hypoxia had enriched HIF-1␣ at 24 h relative to EV cells ( Fig.  3B ). As an additional control, PA-1 cells were transduced with a nontargeting shRNA control sequence (ShC). After incubation in hypoxia, ShC cells displayed substantially greater HIF-1␣ abundance than KD cells ( Fig. 3C ). HIF-1␣ accumulation was next examined in the MiaPaCa-2 line. As shown in Fig. 3D , MiaPaCa-2 KD cells had lower levels of HIF1␣ than EV cells at all time points following exposure to hypoxia, whereas no detectable HIF-1␣ was observed in normoxic populations (positive control, generated from EV cells exposed to hypoxia for 24 h). Correspondingly, HIF-1␣ protein was reduced in hypoxic MiaPaCa-2 KD cells compared with MiaPaCa-2 cells transduced with ShC ( Fig. 3E ). To further verify that ST6Gal-I activity contributes to HIF-1␣ protein levels, an independent ST6Gal-I KD cell line was generated using a ST6Gal-Itargeting shRNA sequence different from that used to engineer KD cells (referred to as KD2). As with MiaPaCa-2 KD cells, hypoxic KD2 cells had diminished HIF-1␣ protein relative to the EV population (Fig. 3F ). The combined results in Figs. 1-3 provide strong evidence that ST6Gal-I activity regulates the hypoxia-dependent accumulation of HIF-1␣.
ST6Gal-I activity provides a proliferative advantage in hypoxic environments
Previous studies by our group have demonstrated that exposure of cells to cytotoxic stimuli or cell stressors exerts selective pressure, leading to the expansion of clonal variants with high ST6Gal-I expression (18, 19, 23, 24, 36, 37) . To determine whether this was true in the context of hypoxia, we cultured parental MiaPaCa-2 cells in a hypoxia chamber for 6 weeks to generate a population capable of proliferating under chronic hypoxia ("hypoxia-adapted"). We then probed for ST6Gal-I expression and found that the hypoxia-adapted population had increased levels of ST6Gal-I relative to the initial parental population ( Fig. 4A ). To determine whether ST6Gal-I provides a growth advantage in hypoxia, we examined the rate of proliferation for MiaPaCa-2 EV and KD cultures exposed to hypoxia for 24, 48, or 72 h (Fig. 4B) . At both 48 and 72 h, a significantly greater number of cells was apparent in EV cells compared with KD cells. Fig. 4C shows representative images for MiaPaCa-2 cells after culture in hypoxia for 72 h. These findings suggest The positive control lysate was from EV cells exposed to hypoxia for 24 h. E, MiaPaCa-2 ShC and KD cells were cultured in hypoxia for 12 or 24 h and then blotted for HIF-1␣. F, MiaPaCa-2 cells transduced with two different shRNA constructs (KD and KD-2) were cultured in hypoxia for 24 h and immunoblotted for HIF-1␣. Lysates were also probed for ST6Gal-I to confirm knockdown.
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that ST6Gal-I activity fosters the maintenance of proliferative potential in cells exposed to a hypoxic microenvironment.
Cells with high ST6Gal-I expression display increased transcription of HIF target genes
Given that ST6Gal-I promoted hypoxia-induced HIF-1␣ accumulation ( Figs. 1-3) , we examined known targets of HIF-1␣ transcription by RT-qPCR. Under hypoxic conditions, OV4 cells with ST6Gal-I OE exhibited significantly greater transcription of GLUT1, GLUT3, and PDHK1 compared with EV cells (Fig. 5, A-C) . Similarly, VEGF␣ mRNA levels were higher in OE cells versus EV cells; however, in this case, OE cells had increased levels of VEGF␣ under both hypoxic and normoxic conditions (Fig. 5D ). In the MiaPaCa-2 cell line, ST6Gal-I KD cells grown in hypoxia displayed significantly reduced transcription of GLUT1, GLUT3, and PDHK1 compared with hypoxic ShC cells (Fig. 6, A-C) . Interestingly, for GLUT3, ST6Gal-I KD also reduced its transcription in normoxia. However, in contrast to the OV4 cell model, ST6Gal-I activity appeared to have no significant effect on VEGF␣ expression in MiaPaCa-2 cells (Fig. 6D ).
ST6Gal-I activity promotes the expression of HIF-1␣ under hypoxic conditions
Because ST6Gal-I sialylates proteins destined for the plasma membrane, we hypothesized that ST6Gal-I activity may affect HIF-1␣ expression. There is extensive literature suggesting that cell surface receptors primarily regulate HIF-1␣ biosynthesis rather than protein stabilization. Accordingly, we examined the effect of ST6Gal-I activity on HIF-1␣ mRNA levels. Fig. 7A shows that OV4 OE cells have higher HIF-1␣ mRNA expression than EV cells after culture in hypoxia for 24 h. In the MiaPaCa-2 line (Fig. 7B ), ST6Gal-I KD cells had reduced expression of HIF-1␣ mRNA compared with ShC control cells under hypoxic conditions. These studies suggest that ST6Gal-I activity may contribute to HIF-1␣ accumulation by increasing HIF-1␣ mRNA pools.
We also quantified the expression of HIF-2␣. Like HIF-1␣, HIF-2␣ is induced by hypoxia; however there is growing literature suggesting that HIF-2␣ is particularly associated with stem-like cancer cells (6) . Moreover, although many of the transcriptional targets for HIF-1␣ and HIF-2␣ overlap, there are some distinct targets for these two factors. For instance, HIF-2␣, but not HIF-1␣, activates the transcription of Oct4 (39) . Oct4 is a master transcription factor that maintains "stemness" in both normal stem cells and CSCs. Intriguingly, overexpression of ST6Gal-I in OV4 cells coordinately increased the mRNA levels of HIF-2␣ and Oct4 under both normoxic and hypoxic conditions (Fig. 7, C and D) . These data are in agreement with our prior studies indicating that forced expression of ST6Gal-I in OV4 cells reprograms cells to adopt a CSC phenotype (18) . However, unlike the OV4 model, MiaPaCa-2 cells did not exhibit significant differences in HIF-2␣ and Oct4 expression (data not shown). Further studies will be needed to dissect the role of ST6Gal-I in regulating the HIF-2␣/Oct4 axis in CSCs.
Discussion
Areas of low oxygen tension are common in rapidly growing tumors because of insufficient vascularization (1) . Tumor cells within these regions respond by activating the HIF pathway, which induces the expression of genes that drive angiogenesis and anaerobic metabolism. These processes are crucial for tumor cell survival. Not surprisingly, HIF signaling is often dysregulated in cancer cells. As an example, the von Hippel-Lindau enzyme, which ubiquitinates HIF-1␣ to target it for proteasomal degradation, is frequently inactivated in various cancers, leading to HIF-1␣ stabilization (40) . HIF-1␣ expression is also up-regulated by oncogenes such as ras, Her-2/neu, and v-src (33, 41) . High levels of HIF-1␣ protein and tissue hypoxia in tumors are correlated with poor patient outcomes as well as tumor resistance to chemo-and radiotherapy (1, (42) (43) (44) (45) (46) . Suppression of HIF-1␣ expression or activity, via RNAi or dominant negative approaches, restores cancer cell responses to chemotherapeutic agents and sensitizes cells to apoptosis induced by oxygen and glucose deprivation (47) (48) (49) . For these reasons, there is a compelling need to define the HIF-directed molecular events that protect tumor cells from hypoxic stress.
In this investigation, we describe a new glycosylation-dependent mechanism that stimulates HIF-1␣ signaling to foster hypoxia adaptation. Using multiple cell models with ST6Gal-I overexpression or knockdown, we show that ST6Gal-I activity augments hypoxia-induced HIF-1␣ accumulation and increases the transcription of HIF-1␣ target genes. In addition, cells with high ST6Gal-I expression have elevated levels of HIF-1␣ mRNA, which may position the cell for greater HIF-1␣ accumulation upon hypoxia-induced HIF-1␣ stabilization. Also important is that long-term culture of cells in low oxygen tension selects for a population with enriched ST6Gal-I expres- 
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sion, substantiating a pro-survival function for ST6Gal-I in hypoxic cells.
In tandem with regulating hypoxic response, HIFs, including HIF-1␣ and HIF-2␣, endow tumor cells with stemlike features (3, 6, 7) . As with ST6Gal-I, HIF-1␣ positively regulates CSC behaviors, including self-renewal, cell invasiveness, and epithelial-to-mesenchymal transition (50, 51) . Moreover, HIFs are major drivers of a metabolic switch toward glycolysis. CSCs have greatly increased glucose uptake relative to more differentiated tumor cells, and CSCs are reportedly dependent on glycolysis for cell growth (50) . Significantly, cells with high ST6Gal-I levels have enhanced expression of GLUT1 and GLUT3. Both of these glucose transporters play a seminal role in CSC survival (52, 53) , and up-regulated GLUT3 is particularly associated with CSCs (53) . HIF-2␣ also contributes to a CSC phenotype by activating the transcription of well-known stem cell genes such as Oct4. In the OV4 ovarian cancer model, ST6Gal-I overexpression increased the levels of HIF-2␣ and Oct4 mRNA under both normoxic and hypoxic conditions. These data are consistent with prior work indicating that ST6Gal-I overexpression reprograms cells into a CSC phenotype (18) . Likewise, ST6Gal-I activity is important for maintaining the stemness of induced pluripotent stem cells (54) .
Further investigation will be needed to fully understand the mechanism by which ST6Gal-I activity potentiates HIF-1␣ signaling. We speculate that ST6Gal-I is more likely to influence HIF-1␣ biosynthesis than HIF-1␣ protein stabilization, given that ST6Gal-I sialylates proteins destined for the plasma membrane (but not cytosolic proteins). Robust literature suggests that cell surface receptors mainly contribute to HIF-1␣ abundance through increasing HIF-1␣ transcription or translation (55) (56) (57) (58) . As one example, the epidermal growth factor receptor signals through phosphatidylinositol 3-kinase/Akt to activate mTOR and stimulate HIF-1␣ translation (59) . On the other hand, the TNFR1/NF-B axis enhances HIF-1␣ transcription (60, 61) , and notably, NF-B binds directly to the HIF-1␣ promoter (62). Our results highlighting elevated HIF-1␣ mRNA in cells with high ST6Gal-I expression hint at a possible role for the TNFR1/NF-B pathway in ST6Gal-I-dependent HIF-1␣ accumulation. Previously we determined that TNFR1 is ␣2-6sialylated by ST6Gal-I and that TNFR1 sialylation abrogates apoptotic signaling (37, 63) . TNFR1 sialylation has been also shown to block receptor internalization, which, in turn, promotes long-term activation of NF-B (37) . Additionally, ST6Gal-I sustains NF-B activation in cancer cells deprived of serum growth factors, thereby preventing exit from the cell cycle and prolonging cell viability (36) .
Regardless of the mechanism by which ST6Gal-I contributes to HIF-1␣ accumulation, this study provides a conceptual advance by elucidating a novel role for a tumor-associated glycosyltransferase in facilitating hypoxia adaptation. Despite decades of evidence that tumor glycans contribute to a malignant cell phenotype, the mechanistic role of receptor glycans in modulating cell signaling remains a markedly underinvesti- 
gated area of cancer research. Accruing literature suggests that ST6Gal-I acts a master regulatory molecule to confer CSC properties that enable tumor cells to survive a plethora of cytotoxic assaults, including oxygen deprivation.
Experimental procedures
Cell culture
MiaPaCa-2 and PA-1 cells were obtained from the ATCC, whereas OV4 cells were a gift from Dr. Timothy Eberlein (Harvard University). For routine propagation, cell lines were cultured in Dulbecco's modified Eagle's medium (MiaPaCa-2 and PA-1) or Dulbecco's modified Eagle's medium/F12 (DME/F12) (OV4) medium, supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) antibiotics/antimycotics (GE Healthcare/Hyclone). For hypoxia mimetic studies, cells were grown in 1% FBS with either DFO or DMOG (both from Sigma) added to the medium at final concentrations of 150 M and 1 mM, respectively (64, 65) . Cells were harvested 24 h after DFO or DMOG treatment. For physiologic hypoxia studies, cells cultured in 1% FBS were placed in a hypoxia chamber for varying times. Hypoxia chambers were set up with varying levels of oxygen tension depending on the cell line. OV4 cells were typically cultured in 2% O 2 , whereas MiaPaCa-2 and PA-1 cells were normally grown in 0.5% O 2 .
Generation of cell lines with variant ST6Gal-I expression
Stable polyclonal cell lines with ST6Gal-I OE were created utilizing a lentivirus encoding the ST6Gal-I gene (Geneco-poeia). Stable KD cells were generated using a lentivirus harboring shRNA against ST6Gal-I. The vectors for KD and KD-2 cells were both from Sigma (KD vector TRCN00000035432, sequence CCGGCGTGTGCTACTACTACCAGAACTCGA-GTTCTGGTAGTAGTAGCACACGTTTTTG; KD-2 vector TCRN0000035433, sequence CCGGGCGCTTCCTCAAAG-ACAGTTTCTCGAGAAACTGTCTTTGAGGAAGCGCTT-TTTG). We also generated control cell lines using an EV (Sigma). Alternatively, cells were stably transduced with ShC (Sigma, catalog no. SHC002V). Stably transduced cells were isolated by puromycin selection. Overexpression or knockdown of ST6Gal-I was verified by immunoblotting using an anti-ST6Gal-I goat polyclonal antibody, as described in more detail below. To confirm that changes in ST6Gal-I expression were correlated with alterations in cell surface ␣2-6 sialylation, cells were stained with the SNA lectin, which specifically binds ␣2-6 sialic acids. Cells were incubated for 40 min at 4°C with a 1:200 dilution of SNA conjugated to DyLight649 (EY Laboratories, DY649-6802-1). Mean fluorescence intensity values were determined by flow cytometry.
Development of hypoxia-adapted cells
MiaPaCa-2 parental cells were cultured in 10% Dulbecco's modified Eagle's medium in a hypoxia chamber containing 2% O 2 for 6 weeks. During this interval, cells were only removed from the chamber to allow passaging to prevent confluency. After 6 weeks of hypoxic culture, the hypoxia-adapted cells 
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or initial parental MiaPaCa-2 cells were immunoblotted for ST6Gal-I.
Proliferation assay
MiaPaCa-2 EV and KD cells were seeded at equal densities in multiple plates and allowed to adhere overnight under standard normoxic conditions. After the overnight incubation, one set of plates was stained with crystal violet to obtain a baseline value for cell number. The remaining plates were placed into hypoxic culture (0.5% O 2 ) for 24, 48, or 72 h. Subsequently, cells were fixed with 4% paraformaldehyde and then stained with a 0.5% (w/v) crystal violet solution (24) . To quantify cell number, the crystal violet-stained cultures were solubilized using a 10% acetic acid solution, and solution absorbance was measured on a Biotek plate reader at 590 nm. Absorbance values for the hypoxic cultures were normalized to the baseline values (overnight culture in normoxia). Three independent experiments were performed, and differences in cell proliferation were assessed by a Student's t test.
Immunoblotting
Cells cultured with either hypoxia mimetics or in physiologic hypoxia were lysed in radioimmune precipitation assay buffer containing protease and phosphatase inhibitors (Thermo). Protein concentrations were quantified by BCA (Pierce). Samples were resolved by SDS-PAGE and transferred onto polyvinylidene difluoride membranes. Membranes were blocked by incubation in 5% nonfat dry milk dissolved in Tris-buffered saline containing 0.1% Tween 20. Membranes were then incubated with primary antibodies against ST6Gal-I (goat polyclonal, R&D Systems, catalog no. AF5924, lot no. CDSF0114101) or HIF-1␣ (Cell Signaling Technology, catalog no. 14179S, lot no. 1). Protein loading was confirmed using either anti-actin (Abcam, catalog no. ab20272, lot no. GR201277) or anti-␤ tubulin (Abcam, catalog no. ab21058, lot no. GR284232). Secondary antibodies conjugated to horseradish peroxidase were incubated with membranes, and protein was detected by enhanced chemiluminescence.
RT-qPCR
RNA was extracted utilizing the Ambion RNA extraction kit (Life Technologies) following the manufacturer's instructions. Complementary DNA was synthesized utilizing M-MLV reverse transcriptase (Promega). Preparation for RT-qPCR samples was implemented using TaqMan Fast Advanced Master Mix (Thermo). Primers for the following gene targets were purchased from Applied Biosystems (Thermo): GLUT1 (catalog no. 4331182, assay ID Hs00892681_m1), GLUT3 (catalog no. 4331182, assay ID Hs00359840_m1), PDHK1 (catalog no. 4331182, assay ID Hs01561847_m1), VEGF␣ (catalog no. 4331182, assay ID Hs00900055_m1), HIF-1␣ (catalog no. 4331182, assay ID Hs00153153_m1), HIF-2␣ (catalog no. 4331182, assay ID Hs01026149_m1), and Oct 4 (catalog no. 4331182, assay ID Hs00999632_g1). Data were normalized to expression of RPLPO (Thermo, catalog no. 4333761F, lot no. 1604105). Significance was determined as p Ͻ 0.05 using a 
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Student's t test from at least three independent experiments, with each experiment performed in triplicate. 
